NVCT
Nuvectis Pharma Inc
20.20$
-6.5%
vs. previous close
Closing price · As of: Sep 25, 2026
Statements
Income Statement
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q1 21 | Q2 21 | Q3 21 | Q4 21 | Q1 22 | Q2 22 | Q3 22 | Q4 22 | Q1 23 | Q2 23 | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | – | – | – | -100.0% | – | – | – | +2,652.3% | -100.0% | – | – | – | – | – | – | -100.0% | – | – | – | – | – | – | |
| – | – | – | – | – | +21.3% | +66.2% | – | – | – | +6.7% | +78.1% | -59.9% | +5.6% | -6.1% | +207.4% | – | – | – | – | – | – | – | |
| – | – | – | – | -73,725.0% | – | – | – | +2,652.3% | -240.7% | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | -2.1% | -72.5% | +57.8% | +38.8% | +80.4% | -2.7% | -46.2% | +80.1% | +5.3% | -4.9% | -37.6% | +10.6% | -4.2% | +59.5% | -18.1% | -1.8% | +59.8% | -11.9% | -19.3% | +14.1% | – | |
| – | +7,260.9% | -69.8% | +118.9% | +1.7% | -6.3% | +32.8% | +67.9% | -27.2% | -12.9% | +10.7% | +55.6% | -33.3% | -2.1% | -9.4% | +26.8% | -3.3% | +57.9% | -32.3% | +25.3% | -14.9% | +16.7% | – | |
| – | +25,717.4% | -21.4% | -51.5% | +30.0% | +21.3% | +66.2% | +14.1% | -39.5% | +40.7% | +6.7% | +11.5% | -36.0% | +5.6% | -6.1% | +47.9% | -13.7% | +18.4% | +18.2% | -2.3% | -17.8% | +15.0% | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | -50.0% | +100.0% | +1,425.0% | +34.4% | -36.6% | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | +9.7% | -100.0% | -4,427.7% | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: September 25, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.